Metabolic syndrome, obesity, diabetes, hypertension, chronic kidney disease (CKD)
Conditions
Interventions
Measurement of MGB1, HRG, microRNAs (mir-221/222, mir-335, mir-342) in serum and plasma samples, and identification of mutations in dyslipidemia-related known genes such as LPL. APOC2, APOC3, APOA5, L
Sponsors
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients with metabolic syndrome, obesity, diabetes, hypertension and chronic kidney disease (CKD), who agree the paticipation in the investigation. The patients will be enrolled regardless of age, gender, out-patient and in-patient.
Exclusion criteria
Exclusion criteria: The patients who are judged as inappropriate for the study and who disagree the enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Diagnosis and classification of dyslipidemia. 2. Identification of mutations for the known responsible genes for the development of dyslipidemia such as LPL. APOC2, APOC3, APOA5, LMF1, GPIHBP1, GCKR, CREB3L3, GPD1. (Since the current study is cross-sectional clinical study, there is no observation period.) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Measurement of HMGB1, HRG, mir-221/222, mir-335, mir-342 in serum and plasma samples. 2. Identification of unknown causal genes for development of dyslipidemia. | — |
Countries
Japan
Contacts
Public ContactNaoko Kurooka
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Nephrology, Rheumatology, Endocrinology and Metabolism
Outcome results
None listed